Multiple Myeloma

Multiple Myeloma: Is MRD Status at 1 Year After Treatment Predictive of Survival?

Results from the Prognostic Immunophenotyping in Myeloma Response (PRIMeR) study, reported in the Journal of Clinical Oncology by Marcelo C. Pasquini, MD, MS, and colleagues...

Breast Cancer
Issues in Oncology

Childhood Adiposity and Risk for Breast Cancer

Investigators have uncovered that a higher adiposity in childhood may lead to less dense tissue formation and decrease the risk of breast cancer...

Gastroesophageal Cancer

Definitive Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Cancer: Comparison of Agents

In a Chinese phase III trial (CRTCOESC) reported in the Journal of Clinical Oncology, Jia et al found that neither capecitabine nor XELOX (capecitabine, oxaliplatin) improved...

Lung Cancer

FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive-Stage SCLC

On May 16, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tarlatamab-dlle (Imdelltra), a bispecific T-cell engager immunotherapy targeting...

Issues in Oncology
Cost of Care

Preferred Sites of Cancer Care: Community Oncology Practices vs Hospitals and Academic Centers

Investigators uncovered that community oncology practices emerged as the preferred sites of service for cancer treatment compared with hospitals and academic...


Sponsored Content

More Top Stories

Hematologic Malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Prostate Cancer

A Delay in Diagnosis Led to Advanced Prostate Cancer

Cancer is not an unfamiliar disease to me. My mother died of cancer when I was 12. My oldest sister died of breast cancer, an aunt died of cancer (I don’t know which type), and my older brother is a prostate cancer survivor. So, when I was diagnosed with prostate cancer in October 2021, the news...


Gallbladder Cancer Rates Among Black Patients in the United States

Gallbladder cancer rates have been stable or declining for most Americans over the past two decades, but cases have steadily risen among Black Americans, with growing numbers of cases not being diagnosed until later disease stages, according to a study presented at Digestive Disease Week 2024...

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

Hepatobiliary Cancer

Pembrolizumab/Chemotherapy for Advanced Biliary Tract Cancer

On October 31, 2023, pembrolizumab (Keytruda) was approved for use with ­gemcitabine/cisplatin in first-line treatment of patients with locally advanced unresectable or metastatic biliary tract cancer.1 Supporting Efficacy Data Approval was based on the double-blind KEYNOTE-966 trial...

NIH’s New Cancer Screening Research Network and Cancer Screening Technologies

The National Institutes of Health (NIH) has launched the Cancer Screening Research Network, a clinical trials network to evaluate emerging cancer screening technologies. The new network will support the Biden-Harris Administration’s Cancer Moonshot initiative by investigating how to identify cancer ...

Outcomes for Cancer Drugs Initially FDA-Approved With Immature Overall Survival Data

In a study reported in The Lancet Oncology, Naci et al identified the degree to which initial U.S. Food and Drug Administration (FDA) approvals of cancer drugs based on immature overall survival data were subsequently followed by reporting of overall survival results. Study Details The study...

Hematologic Malignancies

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin


Pirtobrutinib in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

On December 1, 2023, pirtobrutinib (Jaypirca), a selective, noncovalent  Bruton’s tyrosine kinase (BTK) inhibitor that inhibits both wild-type and C481-mutant BTK with equal low nanomolar potency and is designed to address several of the limitations of covalent BTK inhibitors, was granted...


Onychopapilloma May Be Linked to BAP1 Tumor Predisposition Syndrome

Researchers have discovered that the presence of a benign nail condition known as onychopapilloma may lead to the diagnosis of BAP1 tumor predisposition syndrome, according to a recent study presented by Lebensohn et al at the Society for Investigative Dermatology 2024 Annual Meeting and...